JPWO2020043152A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020043152A5 JPWO2020043152A5 JP2021510019A JP2021510019A JPWO2020043152A5 JP WO2020043152 A5 JPWO2020043152 A5 JP WO2020043152A5 JP 2021510019 A JP2021510019 A JP 2021510019A JP 2021510019 A JP2021510019 A JP 2021510019A JP WO2020043152 A5 JPWO2020043152 A5 JP WO2020043152A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- isolated polynucleotide
- antigen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018103050 | 2018-08-29 | ||
| CNPCT/CN2018/103050 | 2018-08-29 | ||
| CNPCT/CN2019/083918 | 2019-04-23 | ||
| CN2019083918 | 2019-04-23 | ||
| PCT/CN2019/103215 WO2020043152A1 (en) | 2018-08-29 | 2019-08-29 | Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534762A JP2021534762A (ja) | 2021-12-16 |
| JPWO2020043152A5 true JPWO2020043152A5 (enExample) | 2022-09-01 |
| JP7490915B2 JP7490915B2 (ja) | 2024-05-28 |
Family
ID=69643948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510019A Active JP7490915B2 (ja) | 2018-08-29 | 2019-08-29 | 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11932698B2 (enExample) |
| EP (1) | EP3844282A4 (enExample) |
| JP (1) | JP7490915B2 (enExample) |
| KR (1) | KR102879284B1 (enExample) |
| CN (1) | CN112639102B (enExample) |
| AU (1) | AU2019327913A1 (enExample) |
| CA (1) | CA3111087A1 (enExample) |
| IL (1) | IL281098A (enExample) |
| SG (1) | SG11202101773WA (enExample) |
| TW (1) | TW202024330A (enExample) |
| WO (1) | WO2020043152A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017014822A (es) | 2015-05-18 | 2018-04-30 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. |
| CN110536963A (zh) * | 2017-01-26 | 2019-12-03 | 桑格摩生物治疗股份有限公司 | B细胞工程改造 |
| EP3715368A1 (en) * | 2019-03-28 | 2020-09-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells |
| CN119798435A (zh) * | 2019-08-14 | 2025-04-11 | 安托拉诊疗公司 | 与lrp5蛋白结合的抗体及使用方法 |
| CN110964750A (zh) * | 2019-11-13 | 2020-04-07 | 沣潮医药科技（上海）有限公司 | 携带基因元件组合的嵌合抗原受体细胞文库、制备和筛选方法及用途 |
| US12264190B2 (en) * | 2020-04-24 | 2025-04-01 | Astrazeneca Ab | Compositions and methods of treating cancer with chimeric antigen receptors |
| US20240252641A1 (en) * | 2020-05-05 | 2024-08-01 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
| GB202006820D0 (en) * | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| CN115867584A (zh) * | 2020-06-29 | 2023-03-28 | 细胞医学公司 | 用于减少嵌合抗原受体强直信号传导的方法和组合物 |
| CA3133678C (en) * | 2020-08-04 | 2023-04-11 | Cellengene Inc. | Anti-mesothelin chimeric antigen receptor specifically binding to mesothelin |
| GB202012181D0 (en) * | 2020-08-05 | 2020-09-16 | Autolus Ltd | Chimeric receptor |
| WO2022037562A1 (en) * | 2020-08-17 | 2022-02-24 | Nanjing Legend Biotech Co., Ltd. | Engineered immunoresponsive cells and uses thereof |
| EP4263612A4 (en) * | 2020-12-18 | 2025-04-02 | Bioardis LLC | Mesothelin binding molecules and uses thereof |
| EP4294442A4 (en) * | 2021-02-16 | 2025-07-09 | Univ Pittsburgh Commonwealth Sys Higher Education | MESOTHELIN POLYPEPTIDE-BINDING MOLECULES |
| WO2022232277A1 (en) * | 2021-04-27 | 2022-11-03 | TCR2 Therapeutics Inc. | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS AND TGFβR SWITCH |
| AU2022279862B2 (en) * | 2021-05-26 | 2024-02-29 | Cellengene Inc | Chimeric antigen receptor comprising anti-mesothelin scfv, and use thereof |
| WO2022257984A1 (zh) * | 2021-06-08 | 2022-12-15 | 南京驯鹿医疗技术有限公司 | 一种增强型嵌合抗原受体(car)细胞的制备及其应用 |
| WO2023020472A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Mesothelin-targetting antibodies and uses thereof in cancer therapies |
| CN115724942A (zh) * | 2021-09-02 | 2023-03-03 | 广东菲鹏制药股份有限公司 | TGFβRII活性改造突变体及其应用 |
| CN115746123A (zh) * | 2021-09-02 | 2023-03-07 | 广东菲鹏制药股份有限公司 | TGFβRII突变体及其应用 |
| CN114015720A (zh) * | 2021-09-29 | 2022-02-08 | 昆明市延安医院 | 具有靶向高强度杀瘤活性的Mesothelin嵌合抗原受体修饰的T细胞的制备方法 |
| US20240398951A1 (en) * | 2021-10-06 | 2024-12-05 | The Wistar Institute Of Anatomy And Biology | Bispecific t-cell engagers targeting fshr and methods of use in cancer theraputics |
| IL312043A (en) * | 2021-10-14 | 2024-06-01 | Teneobio Inc | Mesothelin binding proteins and their uses |
| KR20240099259A (ko) | 2021-10-14 | 2024-06-28 | 아스널 바이오사이언시스, 인크. | 공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포 |
| US20250242023A1 (en) * | 2021-10-22 | 2025-07-31 | Regents Of The University Of Minnesota | Genetically engineered t cell receptors |
| CN114560949B (zh) * | 2022-03-07 | 2023-09-26 | 中国人民解放军空军军医大学 | 一种具有增强car-t细胞抗肿瘤能力的嵌合抗原受体、d-car-t细胞及其应用 |
| CN116284409A (zh) * | 2022-07-08 | 2023-06-23 | 上海优替济生生物医药有限公司 | Gpc3 car-t细胞及其在制备治疗癌症的药物中的用途 |
| WO2024088371A1 (zh) * | 2022-10-28 | 2024-05-02 | 原启生物科技(上海)有限责任公司 | 靶向msln的抗原结合蛋白 |
| AU2023371779B2 (en) * | 2022-11-02 | 2025-11-27 | Cellengene Inc | Chimeric antigen receptor with increased affinity for mesothelin and use thereof |
| CN116019939A (zh) * | 2022-11-24 | 2023-04-28 | 华中科技大学同济医学院附属协和医院 | 靶向msln的分子探针以及用途 |
| WO2024192534A1 (en) * | 2023-03-23 | 2024-09-26 | National Research Council Of Canada | Anti-mesothelin (msln) single domain antibodies and therapeutic constructs |
| CN118109416B (zh) * | 2023-03-30 | 2024-11-22 | 广州百吉生物制药有限公司 | 功能增强型工程化免疫细胞及其制备和应用 |
| WO2024259305A1 (en) * | 2023-06-14 | 2024-12-19 | The Broad Institute, Inc. | Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof |
| TW202504914A (zh) * | 2023-06-14 | 2025-02-01 | 美商默沙東有限責任公司 | 嵌合抗原受體及其用途 |
| CN119708251A (zh) * | 2023-09-27 | 2025-03-28 | 北京大学 | 一种利用cd27逆转t和car-t细胞pd1信号的工程化细胞方法 |
| CN118147105B (zh) * | 2024-05-09 | 2024-08-02 | 西宝生物科技（上海）股份有限公司 | 一种蔗糖磷酸化酶的高效制备方法 |
| CN119859615A (zh) * | 2024-12-31 | 2025-04-22 | 广州安捷生物医学技术有限公司 | 一种靶向成纤维细胞激活蛋白的car-msc细胞及其制备方法和应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| CA2525286C (en) * | 2003-05-20 | 2012-09-11 | The University Court Of The University Of Glasgow | Materials and methods relating to g-protein coupled receptor oligomers |
| RU2688185C2 (ru) | 2011-03-23 | 2019-05-21 | Фред Хатчинсон Кэнсер Рисерч Сентер | Способ и композиции для клеточной иммунотерапии |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| WO2014004549A2 (en) * | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| AU2013312838B2 (en) | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| JP6307085B2 (ja) | 2012-09-27 | 2018-04-04 | ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｈｅａｌｔｈ ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ | メソテリン抗体および強力な抗腫瘍活性を惹起するための方法 |
| CN102875685B (zh) * | 2012-09-29 | 2013-12-25 | 郑骏年 | 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途 |
| ES2814962T3 (es) | 2013-02-20 | 2021-03-29 | Novartis Ag | Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123 |
| RU2725542C2 (ru) | 2013-05-13 | 2020-07-02 | Селлектис | Способы конструирования высокоактивных т-клеток для иммунотерапии |
| PL2997141T3 (pl) | 2013-05-13 | 2023-02-06 | Cellectis | Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania |
| US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
| CA2931684C (en) | 2013-12-19 | 2024-02-20 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| CN107106665A (zh) | 2014-06-06 | 2017-08-29 | 纪念斯隆-凯特琳癌症中心 | 靶向间皮素的嵌合抗原受体及其用途 |
| JP6839074B2 (ja) * | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
| WO2016160618A2 (en) * | 2015-03-27 | 2016-10-06 | University Of Southern California | Car t-cell therapy directed to lhr for the treatment of solid tumors |
| CN104877032B (zh) | 2015-06-26 | 2018-12-11 | 中国医学科学院血液病医院（血液学研究所） | Cd33特异性嵌合抗原受体及其应用 |
| MX2018002744A (es) | 2015-09-04 | 2018-04-13 | Tocagen Inc | Vectores recombinantes que comprenden peptido 2a. |
| WO2018102795A2 (en) * | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| JP7303749B2 (ja) * | 2017-01-13 | 2023-07-05 | セルダラ メディカル、エルエルシー | Ｔｉｍ－１を標的とするキメラ抗原受容体 |
-
2019
- 2019-08-29 AU AU2019327913A patent/AU2019327913A1/en not_active Abandoned
- 2019-08-29 CN CN201980055889.4A patent/CN112639102B/zh active Active
- 2019-08-29 WO PCT/CN2019/103215 patent/WO2020043152A1/en not_active Ceased
- 2019-08-29 CA CA3111087A patent/CA3111087A1/en active Pending
- 2019-08-29 TW TW108131105A patent/TW202024330A/zh unknown
- 2019-08-29 SG SG11202101773WA patent/SG11202101773WA/en unknown
- 2019-08-29 KR KR1020217009330A patent/KR102879284B1/ko active Active
- 2019-08-29 JP JP2021510019A patent/JP7490915B2/ja active Active
- 2019-08-29 EP EP19854280.5A patent/EP3844282A4/en active Pending
- 2019-08-29 US US17/270,970 patent/US11932698B2/en active Active
-
2021
- 2021-02-24 IL IL281098A patent/IL281098A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020043152A5 (enExample) | ||
| JP7724332B2 (ja) | クローディン１８．２結合部分およびその利用 | |
| KR102068600B1 (ko) | Pdl-1 항체, 그 약학적 조성물 및 그 용도 | |
| CN102369214B (zh) | 三价、双特异性抗体 | |
| KR102838340B1 (ko) | 다중-특이적 항체 및 이들의 제조 및 사용 방법 | |
| AU2020213579B2 (en) | Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| Xiong et al. | Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20× anti-CD3 bispecific diabody | |
| JP2020502233A5 (enExample) | ||
| US20230357398A1 (en) | Novel human antibodies binding to human cd3 epsilon | |
| CN106831995A (zh) | 新型双特异性抗体及其用途 | |
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| WO2023241656A1 (zh) | 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途 | |
| IL322846A (en) | Antibodies, antigen-binding fragments and methods of use | |
| CN113637075A (zh) | 双特异性抗原结合分子及其医药用途 | |
| WO2022188801A1 (zh) | Pd-1结合蛋白及其医药用途 | |
| WO2025016459A1 (zh) | 一种抗fgfr2/pd-1双特异性抗体 | |
| CA2978902A1 (en) | Antibody therapeutics that bind jag1 | |
| CN111518208A (zh) | 抗cd47抗体及其应用 | |
| JPWO2020218951A5 (enExample) | ||
| WO2022127066A9 (zh) | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 | |
| CN114573704B (zh) | Pd-1/ctla-4结合蛋白及其医药用途 | |
| JPWO2021119531A5 (enExample) | ||
| US20260022165A1 (en) | Antibodies targeting cell surface deposited complement protein c3d and use thereof | |
| WO2026057723A1 (en) | Claudin-1/egfr bispecific antibodies for targeted degradation | |
| JPWO2022218380A5 (enExample) |